BridgeBio Pharma (2CL) Ownership - Who Owns BridgeBio Pharma?
BridgeBio Pharma (2CL) Ownership Overview
- 3.95% Insiders
- 26.77% Mutual Funds
- 0.88% Other Institutional Investors
- 12.92% ETFs
- 55.49% Public Companies and Individual Investors
The ownership structure of BridgeBio Pharma (DE:2CL) stock is a mix of institutional, retail, and individual investors. Approximately 40.56% of the company’s stock is owned by Institutional Investors, 3.95% is owned by Insiders, and 55.49% is owned by Public Companies and Individual Investors.
The ownership structure of BridgeBio Pharma (DE:2CL) stock is a mix of institutional, retail, and individual investors. Approximately 40.56% of the company’s stock is owned by Institutional Investors, 3.95% is owned by Insiders, and 55.49% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Nov 18, 2025 | Andrew Lo | $6,319,093 | |
| Nov 13, 2025 | Hannah Valantine | $1,683,728 | |
| Nov 06, 2025 | Ronald J Daniels | $3,888,895 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Bridgewater Associates, Lp | €3,302,226 | |
| Dec 31, 2025 | Platinum Investment Management | €3,652,856 | |
| Dec 31, 2025 | Graham Capital Management, L.p. | €7,729,390 | |
| Dec 31, 2025 | Fisher Asset Management Llc | €17,776,352 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard | 14,716,325 | Institution | 7.55% | 1,111,641,758 |
| Vanguard Index Funds | 13,945,228 | Institution | 7.16% | 1,053,394,633 |
| Andrew J.M. Spokes | 10,743,063 | Institution | 5.51% | 811,509,493 |
| BlackRock, Inc. | 10,287,156 | Institution | 5.28% | 777,071,190 |
| Andreas Halvorsen | 9,949,219 | Institution | 5.11% | 751,544,105 |
| Janus Investment Fund | 5,825,506 | Institution | 2.99% | 440,047,072 |
| Ishares | 5,140,271 | Institution | 2.64% | 388,285,791 |
| Neil Kumar | 5,057,460 | Insider | 2.60% | 382,030,413 |
| Dennis J Purcell | 4,589,611 | Institution | 2.36% | 346,690,036 |
| Vanguard Specialized Funds | 3,162,851 | Institution | 1.62% | 238,915,439 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 13,945,228 | Institution | 7.16% | 1,053,394,633 |
| Janus Investment Fund | 5,825,506 | Institution | 2.99% | 440,047,072 |
| Vanguard Specialized Funds | 3,162,851 | Institution | 1.62% | 238,915,439 |
| Delaware Group Equity Funds V | 2,149,218 | Institution | 1.10% | 162,347,629 |
| Vanguard Explorer Fund | 1,724,983 | Institution | 0.89% | 130,301,766 |
| Fidelity Concord Street Trust | 1,718,099 | Institution | 0.88% | 129,781,762 |
| Columbia Funds Series Trust I | 1,229,427 | Institution | 0.63% | 92,868,457 |
| Jpmorgan Trust Ii | 1,150,147 | Institution | 0.59% | 86,879,804 |
| Fidelity Salem Street Trust | 1,068,563 | Institution | 0.55% | 80,717,112 |
| Lazard Funds Inc | 1,054,465 | Institution | 0.54% | 79,652,177 |
FAQ
Who Owns BridgeBio Pharma (DE:2CL)?
According to the latest TipRanks data, approximately 40.56% of the company's stock is held by institutional investors, 3.95% is held by insiders, and 55.49% is held by public companies and individual investors.
What percentage of BridgeBio Pharma (DE:2CL) stock is held by institutional investors?
According to the latest TipRanks data, approximately 40.56% of BridgeBio Pharma (DE:2CL) stock is held by institutional investors: 26.77% by mutual funds, 12.92% by ETFs and 0.88% by other institutional investors.
What percentage of BridgeBio Pharma (DE:2CL) stock is held by retail investors?
According to the latest TipRanks data, approximately 55.49% of BridgeBio Pharma (DE:2CL) stock is held by public companies and individual investors.
Who owns the most shares of BridgeBio Pharma (DE:2CL)?
Vanguard owns the most shares of BridgeBio Pharma (DE:2CL).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
